Experimental combo for tough lymphoma shows early promise, but trial halted
NCT ID NCT05618366
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a combination of two oral drugs, tazemetostat and venetoclax, in people with non-Hodgkin lymphoma that had come back or stopped responding to treatment. Only 3 people enrolled before the study was terminated. The main goals were to find the safest dose and watch for side effects, not yet to prove the combo works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat and venetoclax (oral drugs)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat non-Hodgkin lymphoma.
- What could go wrong
- This was a very early, small Phase 1 trial that was terminated after enrolling only 3 people. It is too soon to know if the combination is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medicine/NewYork-Presberteryian Hospital
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?